Study on Using Zr-Panitumumab to Detect Suspected Cancer Spread in Head and Neck Cancer

Sponsor: Andrei Iagaru

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT05423197

Provider View

This clinical trial is testing a new imaging method using Zr-Panitumumab to help identify if head and neck cancer has spread to other parts of the body. The study aims to see how well this method works compared to the standard PET/CT scan.

Patient Parameters

Program Overview

The goal of this study is to find out if a new imaging technique using a substance called 89Zr-panitumumab can accurately detect cancer that has spread in patients with head and neck squamous cell carcinoma. Researchers want to see if this method is better at identifying cancer spread compared to the usual PET/CT scans.

Description

The main aim of this study is to determine how well 89Zr-panitumumab can detect cancer that has spread in patients with head and neck cancer. Researchers will measure how sensitive and specific this method is in identifying suspected cancer spread.

Additionally, the study will compare the effectiveness of this new method with the standard PET/CT scans that use a different substance, 18F-FDG, to see which one is better at detecting cancer spread.

Eligibility Criteria

Inclusion Criteria

  • Be 19 years or older.
  • Have a confirmed diagnosis of squamous cell carcinoma in the head and neck area.
  • Can have any size or location of cancer within the head and neck, including new or returning cancer.
  • Must have had a standard PET/CT scan within 30 days before starting the study, showing possible cancer spread.
  • Have acceptable blood, kidney, and liver function, including:
    • Hemoglobin level of at least 9 gm/dL
    • White blood cell count over 3000/mm3
    • Platelet count of at least 100,000/mm3
    • Serum creatinine level no more than 1.5 times the normal range
    • Normal blood clotting times (PTT and INR within specified ranges)

Exclusion Criteria

  • Recent heart attack, stroke, uncontrolled heart failure, serious liver disease, or unstable chest pain within the last 6 months.
  • History of allergic reactions to similar antibody treatments.
  • Pregnant or breastfeeding women.
  • Low magnesium or potassium levels.
  • Taking certain heart rhythm medications (Class IA or Class III antiarrhythmic agents).
  • History or signs of lung inflammation or scarring.
  • Severe kidney disease or inability to produce urine.
  • Known allergy to deferoxamine or its components.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.